Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa

Phase

Condition

Hiv

Lung Disease

Treatment

BCG

MTBVAC

Clinical Study ID

NCT04975178

MTBVACN3

Ages 5-7
All Genders
Accepts Healthy Volunteers

Study Summary

The objective of this project is to demonstrate safety, immunogenicity and improved efficacy of the new live attenuated M. tuberculosis vaccine called MTBVAC in a Phase 3 efficacy trial in HIV-uninfected infants born to HIV-infected and HIV-uninfected mothers as compared to standard of care BCG vaccination. The proposal builds upon a group of TB vaccine development partners in Europe and sub-Saharan Africa established in a previous EDCTP-supported project. It creates an expanded consortium of clinical trial partners for the optimal implementation of a large infant efficacy trial of MTBVAC in high TB incidence settings. New capacity for efficacy trials in infants will be a valuable resource for the TB vaccine development community. The proposal will create a network of institutions in three TB endemic African countries with enhanced laboratory capacity to conduct TB vaccine immunology studies and to bio-bank samples to discover immune correlates of vaccine-mediated protection.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Male or female newborns within seven days of birth.
Written informed maternal consent, including permission to access maternalantenatal, postnatal, and infant medical records.
Infant participants and their caregivers available for trial follow-up and displaythe willingness and capacity to comply with trial procedures.
Newborns must be in good general health during pregnancy and delivery, as assessedby medical history and targeted physical examination.
Birth weight ≥ 2450 grams.
Apgar score at 5 minutes ≥ 7.
A maternal HIV test result (rapid test, enzyme-linked immunosorbent assay (ELISA),or Polymerase chain reaction (PCR)) taken within 30 days of delivery, or withinseven days post-partum must be available and documented if HIV uninfected. If themother is HIV infected, then she must be on antiretroviral (ARV) therapy as perin-country guidelines with a viral load of <50 copies/mL (within six months oflabour).
Estimated gestational age ≥ 37 weeks.
Mother has not participated in a clinical trial within three months prior to theinfant's birth.
Mother has never participated in a TB vaccine trial before.
Infant may not participate in any other clinical trials.

Exclusion

Exclusion Criteria:

Receipt of BCG vaccination prior to enrolment.

Significant antenatal, intrapartum, or postpartum complications that may affect thehealth of the newborn.
Skin condition, bruising or birth mark at the intended injection site.
Maternal HIV test (rapid test, ELISA, or PCR) result not available.
HIV exposed Newborn's HIV PCR result positive or not available.
Maternal history of TB during pregnancy.
History of close/household contact with a TB patient, antenatal or postnatal,whether maternal, other family member or another household member who has not yetcompleted TB treatment.
Clinically suspected neonatal sepsis.
Any severe congenital malformation.
History or evidence of any systemic disease on examination, or any illness that inthe opinion of the Investigator may interfere with the evaluation of the safety andimmunogenicity of the vaccine. Neonatal jaundice not considered clinicallysignificant is not an exclusion.

Study Design

BCG

October 17, 2022

February 28, 2029

Study Description

A new effective tuberculosis (TB) vaccine is essential to achieve World Health Organization End TB goals and eliminate TB by 2050. The optimal long-term strategy would be a combination of serial mass campaigns in adults, coupled with universal newborn vaccination. Newborns are the only human population without prior mycobacterial exposure in TB endemic countries and we hypothesize that live attenuated mycobacterial vaccines will offer better protection to this naïve population compared to adults.

MTBVAC is a novel TB vaccine candidate based on an attenuated M. tuberculosis clinical isolate of the Euro-American lineage. Attenuation is based on two independent, stable genetic deletions of the genes phoP and fadD26 coding for two major virulence factors, the transcription factor PhoP and the cell-wall lipids PDIM, respectively. The hypothesis is that MTBVAC will provide improved protection, as individuals latently infected with live M.tuberculosis have an 80% lower chance of developing TB, and as MTBVAC contains most of the genes deleted from BCG and presents a wider collection of antigens to the host immune system. Preclinical studies in different animal models indicated that MTBVAC is safe and is able to induce an improved protection compared to BCG.

Phase 1 studies showed that MTBVAC was safe and immunogenic in naïve adults and newborns, and evoked an immune response that exceeded the magnitude of BCG-induced immune responses. Larger dose-defining Phase 2a studies in newborns and in adults at extended dose-ranges to confirm these findings will be finalised in early 2021, and allow selection of a vaccine dose to progress into the proposed multi-centre efficacy trial in infants.

Connect with a study center

South African Tuberculosis Initiative, Brewelskloof Hospital
Worcester, Western Cape 6850
South Africa
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.